N	Concordance
1	very 3 weeks. In the absence of grade 4 myelosuppression, paclitaxel was escalat
2	olony stimulating factor can ameliorate myelosuppression (if it is the DLT) to a
3	y combined with severe toxicity such as myelosuppression and pulmonary fibrosis 
4	penia, with no indication of cumulative myelosuppression. Cardiovascular toxicit
5	oma. The nitrosoureas produce a delayed myelosuppression lasting 4 to 6 weeks an
6	premature birth, and maternal and fetal myelosuppression. Breastfeeding should b
7	 patients who ultimately recovered from myelosuppression. Portal of entry was th
8	fections following chemotherapy-induced myelosuppression. A crossover study on t
9	nor gastrointestinal disorders and mild myelosuppression, no adverse reactions w
10	t tissue sarcomas. It produces moderate myelosuppression. Nausea and vomiting ar
11	ndard doses; depending on the degree of myelosuppression experienced after the f
12	e and well-tolerated tool in preventing myelosuppression and infectious complica
13	st significant side-effect is prolonged myelosuppression. Decitabine may show ac
14	t-induction regimens resulted in severe myelosuppression and their toxicity incl
15	ent was not associated with significant myelosuppression, toxicity, or graft-ver
16	pothesis that amifostine attenuates the myelosuppression of carboplatin. Additio